Navigation Links
Waste Management Acquires Certain Assets of MedServe From Stericycle
Date:5/6/2010

HOUSTON, May 6 /PRNewswire-FirstCall/ -- WM Healthcare Solutions, Inc., a subsidiary of Waste Management, Inc. (NYSE: WM), today announced that it has purchased from Stericycle, Inc. (Nasdaq: SRCL) certain assets of MedServe, Inc. MedServe provided regulated medical waste management solutions, including on-site sharps management and on-site medical waste treatment, and waste management solutions for hazardous materials including chemical, pharmaceutical and radioactive waste until its acquisition by Stericycle in December 2009.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090219/WMLOGO)

WM Healthcare Solutions purchased MedServe's Newton, KS, autoclave treatment facility and its transfer stations in Kansas City, KS; Oklahoma City, OK; Omaha, NE; and Booneville, MO. The assets were purchased from Stericycle following a consent decree with the U.S. Department of Justice that resolved its antitrust complaint against Stericycle's acquisition of MedServe, Inc. and that enabled the transaction to close.

"The purchase of MedServe's treatment facility and transfer stations will allow us to provide an increased level of service options for our customers in these states," said David Aardsma, senior vice president of sales and marketing for Waste Managem
'/>"/>

SOURCE Waste Management, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Is Poor Medical Equipment Planning Costing your Healthcare Project Wasted Dollars and Delays? ECRI Institute outlines best practices to ensure better outcomes
2. Dont Let Waste and Inefficiencies Cripple Your Quality Function
3. Dont Let Waste and Inefficiencies Cripple Your Quality Function
4. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
5. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
6. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
7. Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
8. U.S. Preventive Medicine Acquires Specialty Disease Management
9. Cellectar Expands Clinical Management Team
10. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
11. New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Company expands reach of ... big data, aerospace and defense, medical, and industrial, ... engineering R&D services company, today announced professional services ... for aerospace and defense , medical ... industrial , and visual computing applications. ...
(Date:7/29/2014)... Israel , July 30, 2014  Immune ... Stockholm : "IMNP."; "Immune" or "the ... of patients for a Phase II proof of concept ... in the treatment of moderate to severe bullous pemphigoid. ... receive two bertilimumab infusions, at a dose of 10 ...
(Date:7/29/2014)... -- Amgen (NASDAQ: AMGN ) today announced ... results include: , Total revenues increased 11 percent ... driven by strong performance across the portfolio, particularly Enbrel ... (denosumab) and XGEVA ® (denosumab). , ... higher revenues and a significant increase in the profitability ...
Breaking Medicine Technology:eInfochips to Develop NVIDIA GPU-powered Solutions for Aerospace and Defense, Medical Imaging, HPC and Visual Computing 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 3Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 4Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25
(Date:7/30/2014)... July 30, 2014 The family of ... has filed a Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ) ... Bernstein Liebhard LLP reports. According to the complaint, which ... of Vermont on July 25th, the decedent had been ... an irreversible brain bleed that ultimately led to his ...
(Date:7/30/2014)... 30, 2014 Visitors to our region ... $8,500 to ensure its protection. Bob Kiesendahl, one of ... to the Delaware Highlands Conservancy for donations collected through ... $2-per-stay donations add up fast, as visitors welcome the ... Delaware River Region. , The Kiesendahl family has owned ...
(Date:7/30/2014)... July 30, 2014 (HealthDay News) -- Some obese people ... the reward centers in their brains when they see ... how this mutation triggers feelings of pleasure and gratification ... help improve strategies designed to prevent overeating, the scientists ... obese. Obesity is typically caused by a combination ...
(Date:7/30/2014)... 2014 DRE Medical — a leading ... launch of its Medical Trade Shows & Conventions ... professionals and equipment vendors. , The calendar is a ... the United States and around the world. Hundreds of ... number is always growing. , Information listed on each ...
(Date:7/30/2014)... ... ... ... , UCLA researchers interviewed people ... published this week in the peer-reviewed journal Quality of Life Research , a UCLA team led by Dr. Brennan Spiegel interviewed ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:Gene Mutation May Make Food More Tempting 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 3
... higher odds of heart attack, death, study found , , MONDAY, ... younger heart attack patients more prone to another heart attack, ... drug Plavix, researchers report. , The study is published in ... , Plavix plus low-dose aspirin are often used to prevent ...
... Experimental approach seemed to protect the animals from smoke,s ... News) -- In experiments in mice, scientists have shown ... the respiratory damage caused by cigarettes. , The finding ... disease (COPD) -- a chronic progressive lung disease involving ...
... Highway Traffic Safety Administration (NHTSA) revealed that an estimated ... will be on the roads this holiday season. In ... that involved a drunk driver from Thanksgiving through New ... the University of Georgia found that the most important ...
... Department of Energy,s (DOE) Brookhaven National Laboratory have determined ... neurotoxin a deadly toxin produced by certain bacteria ... in cosmetic and therapeutic applications such as reducing wrinkles ... online December 22, 2008, by the Journal of ...
... The Women,s Heart Health Initiative at the Cardiovascular Research ... fellowship dedicated to gender-specific research that will improve the ... The announcement will take place during a February luncheon ... unique challenges to successful diagnosis and treatment of heart ...
... Medicine (BUSM) have determined the optimal dose-management strategy to ... outcomes. Results of the study appear online in the ... and Haemostasis . , Warfarin is highly effective ... conditions. Numerous studies have focused on the underutilization ...
Cached Medicine News:Health News:Gene Ups Risk for Those on Blood-Thinner Plavix 2Health News:Gene Ups Risk for Those on Blood-Thinner Plavix 3Health News:Drug Shields Mice From Emphysema 2Health News:MU professor recommends changing drivers' perceptions of law enforcement to deter drunk driving 2Health News:Scientists reveal structure of new botulism nerve toxin subtype 2Health News:Scientists reveal structure of new botulism nerve toxin subtype 3Health News:Study shows optimal dose management of warfarin improves anticoagulation control 2
The torso blanket is designed to affix to the lower abdominal area and cover the upper half of the body....
The torso blanket is designed to affix to the lower abdominal area and cover the upper half of the body....
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
Medicine Products: